BROWN BROTHERS HARRIMAN & CO - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
BROWN BROTHERS HARRIMAN & CO ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$1,697
+3.5%
2,8500.0%0.00%
Q2 2023$1,639
-18.2%
2,8500.0%0.00%
Q1 2023$2,003
-68.9%
2,8500.0%0.00%
Q4 2022$6,441
-28.4%
2,8500.0%0.00%
Q3 2022$9,000
-18.2%
2,8500.0%0.00%
Q2 2022$11,000
-26.7%
2,8500.0%0.00%
Q1 2022$15,000
-61.5%
2,8500.0%0.00%
Q4 2021$39,000
-23.5%
2,8500.0%0.00%
Q3 2021$51,000
+4.1%
2,8500.0%0.00%
Q2 2021$49,000
-14.0%
2,8500.0%0.00%
Q1 2021$57,000
+18.8%
2,8500.0%0.00%
Q4 2020$48,000
+2.1%
2,8500.0%0.00%
Q3 2020$47,000
-28.8%
2,8500.0%0.00%
Q2 2020$66,000
+29.4%
2,8500.0%0.00%
Q1 2020$51,000
-17.7%
2,8500.0%0.00%
Q4 2019$62,000
+17.0%
2,850
-1.2%
0.00%
Q3 2019$53,000
-47.5%
2,885
+1.2%
0.00%
-100.0%
Q2 2019$101,0002,8500.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
Camber Capital Management LP 3,500,000$60,060,0002.02%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,772,0001.42%
Rhenman & Partners Asset Management AB 950,000$16,302,0001.11%
MAVERICK CAPITAL LTD 5,761,073$98,860,0000.93%
Birchview Capital, LP 72,000$1,236,0000.74%
Bellevue Group AG 4,101,404$70,380,0000.69%
CM Management, LLC 50,000$858,0000.62%
Duquesne Family Office 1,000,000$17,160,0000.42%
OSTERWEIS CAPITAL MANAGEMENT INC 373,368$6,407,0000.33%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,149,0000.30%
View complete list of NEKTAR THERAPEUTICS shareholders